Sanofi COVID-19 vaccine not ready in 2021: CEO Paul Hudson
Paris: A COVID-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper.
Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer/BioNTech and Moderna --, are expected to start this quarter.
In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data.
"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue," Paul Hudson was quoted as saying.
The CEO gave no other details. Officials at Sanofi were not available for comment.
The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.